that supplementation with vitamin D has modest effects on ventricular function and N-terminal brain natriuretic peptide levels among patients with HF. 6 The role of calcium in HF pathogeneses is not clear. There are no existing data on the direct effect of calcium supplementation on HF. However, results from 2 meta-analyses suggest that calcium may be associated with increased risk of some cardiovascular diseases (CVD). Bolland et al 11 reported calcium (alone) supplementation to be associated with a significant 27% increased risk of myocardial infarction in a pooled sample of 12 000 trial participants, while Wang et al 12 reported a 14% elevated risk of a composite of CVD associated with calcium (alone) supplementation. However, combined supplementation of calcium and vitamin D had a null effect on CVD incidence. 12 Hsia et al 13 previously reported that vitamin D plus calcium (CaD) supplementation did not increase the risk of CVD, including HF, in the Women's Health Initiative CaD trial population. Their analyses involved participants with preexisting HF at baseline; hence, it is not clear what the effect of the intervention was on women free of HF at baseline. The present analyses, therefore, evaluate the effect of randomized assignment to CaD supplementation in the prevention of HF among postmenopausal women free of HF and participating in the Women's Health Initiative CaD trial. Secondary prespecified goals for the present analyses were to examine the results in high-risk versus low-risk groups and according to baseline intake of personal vitamin D and calcium supplements. Hypertension, diabetes mellitus, and CVD, associated with HF population attributable risks of 59%, 12%, and 26%, respectively, among US women aged 40 to 80 years old 14 are also associated with low serum vitamin D levels. 6, 12, [14] [15] [16] [17] Hence, vitamin D supplementation may have HF benefits in populations with these pre-existing chronic conditions. Prespecified sensitivity analysis included per-protocol analysis and estimation of CaD effects through inverse probability of censored weights methods. 18
Methods

Design Overview: The CaD Trial
This is a secondary analysis of HF outcomes from a previously completed randomized control trial testing the effects of CaD on fractures and cancer outcomes as primary end points; however, CVD including HF were also ascertained. The CaD trial design and methodology have been published. 19, 20 This study was approved by an institutional review committee and all subjects gave informed consent.
Randomization and Intervention
The 36 282 postmenopausal women, aged 50 to 79 years old, who met the inclusion criteria and consented to participate in the CaD trial were randomized in a 1:1 ratio double-blinded fashion to receive either the intervention or placebo. The intervention group received a total dosage of 1000 mg elemental calcium and 400 IU vitamin D 3 per day. 19, 20 This dose, according to the Institute of Medicine (IOM), was sufficient to meet the recommended dietary allowance of both vitamin D and calcium in postmenopausal women. Participants randomized to the placebo group were provided inactive tablets that looked exactly like the active tablets and instructed to take these tablets in the same format as those in the intervention group to preserve the blinding of the randomization to both study staff and participants. 19 Participants who reported use of personal vitamin D (48.4%) and calcium (54.9%) supplements were allowed to continue taking them even after enrolling in the CaD trial. The personal vitamin D supplement consumption was later raised to an upper limit of 1000 IU/d after the IOM published new recommendations on vitamin D intake in 1999. 21 Details of participant selection for the CaD trial and the present analyses are reported in Figure 1 .
Outcome: Ascertainment of HF Cases
Trained staff abstracted medical records annually for self-reported HF hospitalization and any 2-day hospitalization that reported a CVD outcome. The abstracted HF cases were then classified by an adjudication committee of physicians at local clinical sites; only a subset of HF cases were adjudicated by a central adjudication physician committee because HF was a secondary end point for the CaD trial. The local and central adjudication methods had an excellent 79% agreement rate (k). 22 The local physician committee used the following method: hospitalized HF (HF requiring and occurring during hospitalization) required physician diagnosis of new-onset or worsened congestive HF on the reported hospital admission and ≥1 of the following 4 criteria: (1) HF diagnosed by physician and receiving medical treatment for HF; (2) above plus documentation in the current medical record of a history of an imaging procedure showing impaired left ventricular systolic or diastolic function; (3) pulmonary edema/congestion on chest x-ray on the current admission; (4) dilated ventricle(s) or poor left ventricular or right ventricular function by echocardiogram, multigated acquisition, radionuclide ventriculogram, or other contrast ventriculography, or evidence of left ventricular diastolic dysfunction.
Covariates and Effect Modifiers
We stratified the study sample into 2 subgroups by baseline status of medical histories of major cardiovascular precursors of HF to estimate the effect of CaD intervention in these subgroups. For the prespecified subgroup analyses, we defined high risk using American College of Cardiology criteria, based on the presence of hypertension, diabetes mellitus, CHD, or CVD. 23 Women who reported any histories of medically diagnosed hypertension, diabetes mellitus, CHD, or CVD before randomization were grouped as high risk of HF while those without any of these conditions were considered to be at low risk of HF.
Self-reported histories of physician-diagnosed cardiovascular conditions were obtained from all participants during trial enrollment. Details of the description of these baseline factors and other baseline potential confounders listed in Table 1 have been previously reported. 19 Hypertension was defined as a self-reported physician diagnosis of hypertension with or without current use of antihypertensive medications or high blood pressure (BP) (measured systolic BP ≥140 mm Hg and diastolic BP ≥90 mm Hg) during enrollment into the CaD trial. CVD was defined as self-reported physician diagnosis of problems with the heart, blood circulation, or clots. CHD was defined as a composite of self-reported cardiac arrest, angina, coronary artery bypass graft surgery, and percutaneous transluminal coronary angioplasty. Diabetes mellitus was defined based on self-reported physician diagnosis of diabetes mellitus and current prescription of diabetic medications.
Sample Size and Power Calculations
Women (153 intervention; 146 placebo) with prior medical diagnosis of HF at trial enrollment were excluded from this analysis to create a primary prevention cohort of 35 983 (18 023 intervention; 17 960 control) postmenopausal women free of HF. When stratified by baseline risk status of HF, 17 449 (8716 intervention; 8733 control) were considered to be at high risk while 18 534 (9307 intervention; 9227 control) were considered to be at low risk. A total of 744 HF cases occurred (high-risk: 587 [302 intervention; 285 control] versus lowrisk subgroup: 157 [61 intervention; 96 control]) during a total follow-up of ≈9.8 years. Based on these data and an α level of 0.05, this study had 80% statistical power to detect protective effects (hazard ratios [HR]) of CaD supplementation of ≥0.86, 0.64, and 0.78 in the overall CaD cohort, the low-risk, and high-risk subgroups, respectively. 24 Given a 2-tailed a priori hypothesis testing, the study was powered at 80%, type I error of 0.05, to detect interaction effect sizes of ≥1.52 when CaD effect is stronger in the high-risk compared with the low-risk group or ≤0.66 when CaD effect is stronger in the lowrisk compared with the high-risk group. 25
Statistical Analysis
All main analyses were performed based on an intention-to-treat approach. Chi-square and Student t test were performed to assess the balance of potential confounders between trial arms for the entire CaD cohort and by stratified subgroups. Cox proportional hazard regression models were used to estimate the effect (HR) of the intervention on HF. Both graphical, Kaplan-Meier curves ( Figure 2 ) and Schoenfeld residuals plots ( Figure I in the Data Supplement) and time-dependent proportionality tests (study cohort [P for interaction]; overall cohort (0.45), low risk [0.80], high risk [0.44]) were used to evaluate whether the proportionality assumption was violated by the intervention variable. Formal test of interaction between the randomization status and a binary indicator of baseline HF risk status was performed by including a product term between the 2 variables in the Cox proportional hazard models. All HRs were estimated from unadjusted Cox proportional hazard models because all potential covariates evaluated were balanced between the 2 arms of the study.
We also evaluated whether personal consumption of vitamin D or calcium supplements at baseline modified the effect of CaD on HF incidence because participants were allowed to continue consuming their personal calcium and vitamin D supplements after enrolling in the CaD trial. In addition, we tested whether total (diet plus supplements) vitamin D or calcium intake modified the effect of CaD on HF incidence. We also estimated a potential effect modification by self-reported postmenopausal hormone therapy and randomization to receive intervention in the hormone replacement therapy trial.
Sensitivity analyses were performed by restricting the analyses to only participants who achieved ≥80% adherence rate to study medication (n=23 601, 65.6%). To estimate CaD effects (HRs) independent of censoring information, the inverse probability of censored weights method was implemented. 18, 26 The inverse probability of censored weights model was adjusted for some of the factors previously reported as strong predictors of adherence to study medication in the CaD trial-age, education level, use of personal calcium, vitamin D or multivitamin supplements, history of HF risk factors, family history of CVD, and enrollment in other clinical trials. 27
Results
Baseline sociodemographic, physical/lifestyle, and clinical factors were proportionally distributed between the 2 study arms for the entire CaD cohort ( Table I in the Data Supplement) and in the 2 stratified subgroups of participants with and without major precursors of HF (Table II in prevalent in the high-risk group compared with the low-risk group; however, personal calcium and vitamin D supplements consumption was proportional between these subgroups (Table 1 ). There were 744 HF cases (29.0/10 000 personyears) during a median follow-up of 7.06 years (interquartile range: 1.61); 363 (28.2/10 000 person-years) of these occurred in the intervention arm versus 381 (29.8/10 000 person-years) in the placebo arm. When stratified by baseline risk status, more HF cases occurred in the high-risk subgroup (587 [302 intervention; 285 control]) than in the low-risk subgroup of women (157 [61 intervention; 96 control]), P value of difference <0.001. Supplementation with CaD was not associated with risk of HF hospitalization in the overall cohort, HR, 0.95 (95% confidence interval [CI], 0.82-1.09); P=0.46. The effect of CaD, however, was modified (P for interaction=0.005) by baseline risk status of HF (defined by the presence or absence of CHD, other CVD, hypertension, or diabetes mellitus) at baseline. When stratified by baseline risk status, CaD was associated with a statistically significant 37% lower risk of HF, HR, 0.63 (95% CI, 0.46-0.87); P=0.005 (number neededto-treat, 255 [95% CI, 174-723] in the low-risk subgroup), but not in the high-risk subgroup (HR, 1.06 [95% CI, 0.90-1.24]) ( Figure 3 ). Consumption of personal vitamin D (P for interaction=0.33) or calcium (P for interaction=0.11) supplements did not modify the effect of CaD on HF incidence. The effects of CaD were also not modified by baseline selfreported total (diet plus supplements) consumption of vitamin D (P for interaction=0.26) or calcium (P for interaction=0.81; Table 2 ). Neither assignment to receive the intervention (estrogen alone or estrogen plus progestin) nor self-reported use of postmenopausal hormone therapy at baseline modified the effect of CaD on HF incidence ( Table 2 ). Baseline covariates also did not confound these associations in multivariableadjusted Cox proportional hazard regression models.
The intention-to-treat and per-protocol results were similar (Table 3 ). In the per-protocol analysis, CaD was not also associated with HF in the overall cohort or in the high-risk subgroup but was associated with a significantly reduced risk of HF in the low-risk subgroup ( Table 3 ). Similar CaD effects were observed among women who did not report taking personal vitamin D and calcium supplements and were also independent of competing events when estimated with the inverse probability of censored weights methods ( Table III in 
Discussion
Vitamin D and calcium supplementation was associated with lower risk of HF in a subgroup of women without preexisting HF precursors at baseline but had no effect in those with these conditions. These findings were independent of baseline total vitamin D and calcium intake and persisted in per-protocol analysis. Results from a recent meta-analysis of 17 trials (n=12 440), including the Medical Research Council Randomised Evaluation of Calcium Or vitamin D (RECORD) trial, showed that vitamin D alone (versus placebo) was associated with a 21% lower risk of cardiac failure (HR, 0.79 [95% CI: 0.60-0.98]; P=0.03) among men and women with a mean/median age >60 years old. 28 It is not clear whether the observed effect of vitamin D supplementation might have differed between baseline populations stratified by pre-existing HF precursors in the meta-analysis population.
The basis for the differential effects of CaD intervention on HF incidence by baseline risk status is uncertain. Data from animal models suggest vitamin D may regulate cardiac functions, at least partially, via interaction with the vitamin D receptors in cardiaomyocytes. 2, 3 Through a receptormediated mechanism, 1,25(OH) 2 D regulates intracellular calcium homeostasis and calcium ion uptake in ventricular cardiac muscle cells to modify cardiac contractility. 29 An intermediate pathophysiological model involving the upregulation of the renin-angiotensin-aldosterone system has been observed in both human and animal studies. Reninangiotensin-aldosterone system plays a major role in HF pathogenesis by regulating BP, cardiac contractility, electrolyte homeostasis, and eccentric hypertrophy of the myocardium. 30, 31 It has been demonstrated that a knockout model of mice without the vitamin D receptors develop high BP, cardiac enlargement, and experience increased activation of the renin-angiotensin-aldosterone system. 32 The activation of renin-angiotensin-aldosterone system by low vitamin D status has recently been suggested in humans based on observational studies. 33, 34 However, a meta-analysis of 10 trials did not show an association between vitamin D (alone or with calcium) supplementation and reduction in either systolic or diastolic BPs. 16 Hyperparathyroidism has also been postulated as an intermediate process in the vitamin D-HF pathophysiology. Data from patients with end-stage renal disease suggests secondary hyperparathyroidism, and elevated parathyroid hormone levels were associated with low vitamin D levels caused by failure of the kidneys to convert 25(OH)D to the metabolically active form of 1,25(OH)D 2 . 2, [8] [9] [10] Chronic exposure to parathyroid hormone has been reported to be associated with poor myocardial structure and functioning, as well as elevated BP and accelerated atherosclerosis. It is, therefore, plausible the lower risk of HF observed in the low-risk subgroup is a result of the ability of the vitamin D supplements to prevent or mitigate the process of hyperparathyroidism.
We expected that the high-risk subgroup would benefit more from the intervention, based on evidence that vitamin D deficiency is relatively higher in this subgroup in the general population, but our data did not confirm this hypothesis. One plausible explanation for the lack of an association between CaD and HF incidence in the high-risk subgroup is that HF pathogenesis was already too advanced to be influenced by the CaD supplements. Thus, in this high-risk population, any potential benefit related to HF prevention may have been diminished. Our data suggest that the high-risk group may indeed have poorer health status compared with those free of these comorbidities; baseline factors associated with poor health and risk of HF, such as older age, obesity, and hypercholesterolemia, were predominantly prevalent in this highrisk subgroup (Table 1) .
It is also plausible that medical therapy for management of the cardiovascular risk factors in the high-risk group may have modified the effect of CaD intervention on HF. We, therefore, evaluated whether the use of CVD medications such as angiotensin-converting enzymes inhibitors, angiotensin II receptor blockers, statins, β-blockers, or calcium channel blockers were effect modifiers. Individually and collectively (composite of CVD medications), CVD medications did not significantly interact with CaD in relation to HF except angiotensin II receptor blockers (P for interaction=0.04; Material in the Data Supplement). This supports the possibility that CaD supplementation may interact with medications used to treat comorbidities, thus making any direct effect of the intervention on HF outcome more difficult to detect. Additional studies on this topic are warranted.
This study contributes to the growing literature on the association between vitamin D and lower incidence of HF. This study is probably the first to demonstrate that CaD supplementation may be associated with lower risk of HF among postmenopausal women without pre-existing hypertension, diabetes mellitus, CHD, or other CVD but not in those with these conditions. The study had adequate statistical power to perform the prespecified subgroup analysis. The randomized trial design nature of the data minimized the effect of potential confounders.
Despite the strengths of this randomized trial, limitations of the study also warrant consideration. First, as a result of combining calcium with vitamin D as the intervention, it is unclear whether the observed associations are because of one or both of these dietary supplements. However, based on the metaanalysis 26 report that suggested an association between vitamin D (alone) supplementation and lower risk of HF and other reports that suggest calcium (alone) may be associated with increased risk of CVD events, it can be inferred that vitamin D was the active agent responsible for the prevention of HF in the Women's Health Initiative trial. Second, the CaD trial was limited to postmenopausal women, 50 to 79 years old, which may preclude generalizability of the findings to men or to younger women. Last, for ethical reasons, participants were allowed to continue consumption of both vitamin D and calcium supplements within the recommended dietary allowance guidelines put forth by the Institute of Medicine. However, consumption of personal vitamin D and calcium supplements did not modify the effect of CaD on HF incidence.
Our findings suggest that a low cost daily supplementation with vitamin D (400 IU) plus calcium (1000 mg) may be an Table 3 effective primary prevention strategy for HF in postmenopausal women free of pre-existing cardiovascular conditions. However, it seems to be of little value in preventing HF in the overall trial population and the subgroup of postmenopausal women who already have CVD conditions, including CHD, diabetes mellitus, and hypertension. These findings, if confirmed by other research, may have important public health and clinical implications.
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